Cas9 Stable Cell Line - A-375

The Cas9-stable A-375 cell line is a genetically engineered variant derived from the human malignant melanoma cell line A-375. The parental cell line was originally isolated from a metastatic skin tumor in a 54-year-old female patient. This modified A-375 cell line stably integrates the CRISPR-associated protein 9 (Cas9) endonuclease, thereby enabling continuous and highly efficient genomic editing capabilities without the need for repeated transfection procedures. Its parental cell line, A-375, exhibits aggressive tumorigenic characteristics specific to melanoma, including high metastatic potential, a high incidence of the BRAF V600E mutation, and dysregulation of the MAPK signaling pathway. The Cas9-stable A-375 cell line demonstrates a robust proliferation rate and maintains consistent Cas9 expression levels across more than 100 passages, while retaining melanoma-specific biomarkers such as S100 and HMB-45. Owing to its exceptionally high transfection efficiency and excellent compatibility with various sgRNA delivery methods, this cell line proves highly suitable for conducting precise genetic manipulations in the field of skin oncology research.

In functional genomics studies, the Cas9-stable A-375 cell line can be utilized to perform genome-wide CRISPR knockout screens, enabling the identification of key factors driving tumor metastasis, drug resistance, or immune evasion by targeting signaling pathways such as MAPK/ERK, PI3K/AKT, and WNT. Researchers can leverage this cell line to construct isogenic cellular models—by precisely knocking out tumor suppressor genes (e.g., PTEN) or knocking in drug-resistance mutations (e.g., NRAS Q61K)—to subsequently evaluate the efficacy of targeted therapies, such as BRAF inhibitors (e.g., Vemurafenib) and MEK inhibitors. In the realm of immunotherapy research, this cell line facilitates the knockout of immune checkpoint genes (e.g., PD-L1 and CTLA-4) using CRISPR technology, thereby enabling the assessment of T-cell cytotoxicity and the simulation of responses to combination therapy regimens. Furthermore, by engineering the integration of reporter genes into loci such as MITF or SOX10, this cell line facilitates the accelerated discovery of biomarkers and enables the monitoring of dynamic changes in cellular phenotypic plasticity during the process of epithelial-mesenchymal transition (EMT).